Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TCON

TCON - Tracon Pharmaceuticals Inc Stock Price, Fair Value and News

$16.91-0.01 (-0.06%)
Market Closed

76/100

TCON

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

76/100

TCON

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$25.16

Target 3M

$18.67

Target 6M

$20.62

TCON Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TCON Price Action

Last 7 days

0.2%

Last 30 days

1.0%

Last 90 days

1.1%

Trailing 12 Months

7.8%

TCON RSI Chart

TCON Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TCON Valuation

Market Cap

54.8M

Price/Earnings (Trailing)

10.55

Price/Sales (Trailing)

4.55

Price/Free Cashflow

5.96

TCON Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$25.16

Target 3M

$18.67

Target 6M

$20.62

TCON Fundamentals

TCON Revenue

TCON Earnings

TCON Profitability

Free Cashflow Yield

16.79%

TCON Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202306.2M9.1M12.0M
20210346.0K346.0K3.3M
201811.1M10.5M3.0M3.0M
20172.9M2.7M9.4M8.8M
20168.0M4.6M4.2M3.4M
20154.4M7.5M7.5M7.9M
20140003.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Tracon Pharmaceuticals Inc

TCON
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
 CEO
 WEBSITEtraconpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES18

Tracon Pharmaceuticals Inc Frequently Asked Questions

TCON is the stock ticker symbol of Tracon Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Tracon Pharmaceuticals Inc is 54.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TCON's fair value in chart for subscribers.

The fair value guage provides a quick view whether TCON is over valued or under valued. Whether Tracon Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Tracon Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TCON.

As of Wed Jan 28 2026, TCON's PE ratio (Price to Earnings) is 10.55 and Price to Sales (PS) ratio is 4.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TCON PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Tracon Pharmaceuticals Inc has provided -0.391 (multiply by 100 for percentage) rate of return.